Phio Pharmaceuticals Corp. announced on April 9, 2025, that its Safety Monitoring Committee (SMC) recommended dose escalation in the Phase 1b clinical trial for PH-762. This recommendation allows the study to advance to the fourth dose escalation cohort, continuing to evaluate the safety and tolerability of intratumoral PH-762 in various skin cancers.
In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. Injections were well tolerated, with no serious adverse events and no dose-limiting toxicities reported. Pathology results related to the efficacy of PH-762 in the third cohort are forthcoming.
Previously, in the second cohort, two patients achieved a complete response (100% tumor clearance), and one patient had a partial response (90% clearance). All three patients in cohort 1 and one patient in cohort 2 maintained stable disease. Robert Bitterman, President and CEO, expressed optimism that the clinical trial will continue to demonstrate PH-762 as a viable non-surgical alternative for skin cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.